Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer.

Exp Hematol Oncol · 2026 · PMC13244906 · PMID 42260640

Europe PMC DOI

hedged sentence

0.0511

closest p · 1.0× alpha

0.0511

boldest claim

The sentences

a clear trendp = 0.0511so close (0.05 < p ≤ 0.1)

did not reach statistical significancep = 0.0511so close (0.05 < p ≤ 0.1)

Although tumor count reduction did not reach statistical significance, a clear trend favoring the combination was observed ( p = 0.0511) (Fig. 1 C).

also in 12,254 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.